Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for thyroid eye disease: drug targets bulging eyes and double vision

NCT ID NCT07152392

First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 32 times

Summary

This study tests a drug called IBI311 in 50 adults with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. The drug works by blocking a specific receptor to reduce swelling and tissue growth behind the eyes. Researchers will measure improvements in eye bulging and double vision, and monitor for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Changzheng Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200003, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.